Overview
Extreme drug-resistant tuberculosis (XDR-TB) refers to a form of tuberculosis caused by bacteria resistant to isoniazid and rifampin, along with any fluoroquinolone and at least one of three injectable second-line drugs (amikacin, kanamycin, or capreomycin). This condition poses significant therapeutic challenges due to limited treatment options and higher mortality rates [Not directly covered in provided abstracts].Diagnosis
Clinical Presentation: Symptoms include chronic cough, weight loss, fever, and night sweats [Not directly covered in provided abstracts].
Laboratory Tests: Sputum culture and drug susceptibility testing essential to confirm resistance patterns [Not directly covered in provided abstracts].
Imaging: Chest X-rays often show upper lobe infiltrates, cavitation, or pleural effusion [Not directly covered in provided abstracts].Management
First-Line Treatment: Combination therapy with second-line drugs tailored to resistance profile (e.g., fluoroquinolones, injectables, and ethionamide or cycloserine) [Not directly covered in provided abstracts].
Adjunctive Therapies: Supportive care including nutritional support, corticosteroids for severe forms, and management of complications [Not directly covered in provided abstracts].
Monitoring: Regular sputum cultures and clinical assessments to monitor response and resistance development [Not directly covered in provided abstracts].Special Populations
Pregnancy: Limited data; management focuses on minimizing teratogenic risks while treating the mother [Not directly covered in provided abstracts].
Pediatrics: Neonatal and pediatric cases require careful consideration of developmental impacts and tailored dosing [Not directly covered in provided abstracts].
Comorbidities: Presence of HIV significantly complicates treatment and prognosis; antiretroviral therapy integration is crucial [Not directly covered in provided abstracts].Key Recommendations
Proactive Management in Extremely Premature Infants: Disagreement between obstetricians and neonatologists regarding proactive management (e.g., antenatal steroids, cesarean delivery) increases early neonatal mortality risk 1. (Evidence: Moderate)
Intensive Care at Gestational Ages 26 Weeks and Above: Consensus supports providing intensive care at 26 weeks gestation, with grey area for 24-25 weeks 2. (Evidence: Expert opinion)
Antenatal Steroid Therapy: Use of antenatal steroids is associated with improved outcomes in extremely low birth weight infants 4. (Evidence: Moderate)
Resuscitation Practices: Resuscitation generally restricted to infants of 23 weeks' gestation or above in Australia, with neonatologists primarily responsible for decisions 3. (Evidence: Expert opinion)References
1 Guinsburg R, Branco de Almeida MF, Dos Santos Rodrigues Sadeck L, Marba ST, Suppo de Souza Rugolo LM, Luz JH et al.. Proactive management of extreme prematurity: disagreement between obstetricians and neonatologists. Journal of perinatology : official journal of the California Perinatal Association 2012. link
2 Vavasseur C, Foran A, Murphy JF. Consensus statements on the borderlands of neonatal viability: from uncertainty to grey areas. Irish medical journal 2007. link
3 Munro M, Yu VY, Partridge JC, Martinez AM. Antenatal counselling, resuscitation practices and attitudes among Australian neonatologists towards life support in extreme prematurity. The Australian & New Zealand journal of obstetrics & gynaecology 2001. link
4 Kitchen WH, Permezel MJ, Doyle LW, Ford GW, Rickards AL, Kelly EA. Changing obstetric practice and 2-year outcome of the fetus of birth weight under 1000 g. Obstetrics and gynecology 1992. link